Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 678-687

  Romer, Daniela ^a   Brighty, David W ^b   Robson, Cynthia L ^a   Sattentau, Quentin J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; DEXTRAN SULFATE; PRO 2000; PROTEIN GP46; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL FUSION; CELL SURFACE; CELL TRANSFER; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CELL FUSION; CELL SURVIVAL; CELLS, CULTURED; GENE PRODUCTS, ENV; HELA CELLS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; NAPHTHALENESULFONATES; PEPTIDES; POLYMERS; RETROVIRIDAE PROTEINS, ONCOGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRION;

EID: 59749100334     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01550-07     Document Type: Article

References (53)

1. Anderson, R. A., K. A. Feathergill, X. H. Diao, M. D. Cooper, R. Kirkpatrick, B. C. Herold, G. F. Doncel, C. J. Chany, D. P. Waller, W. F. Rencher, and L. J. Zaneveld. 2002. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J. Androl. 23:426-438.
2. Baba, M., R. Pauwels, J. Balzarini, J. Arnout, J. Desmyter, and E. De Clercq. 1988. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 85:6132-6136.
3. Baba, M., R. Snoeck, R. Pauwels, and E. de Clercq. 1988. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob. Agents Chemother. 32:1742-1745.
4. Balzarini, J., Y. Van Herrewege, K. Vermeire, G. Vanham, and D. Schols. 2007. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 71:3-11.
5. Bartholomew, C., W. C. Saxinger, J. W. Clark, M. Gail, A. Dudgeon, B. Mahabir, B. Hull-Drysdale, F. Cleghorn, R. C. Gallo, and W. A. Blattner. 1987. Transmission of HTLV-I and HIV among homosexual men in Trinidad. JAMA 257:2604-2608.
6. Belec, L., M. C. Georges-Courbot, A. Georges, A. S. Mohamed, D. Londos-Gagliardi, M. C. Hallouin, H. Hocini, and B. Guillemain. 1996. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I. J. Med. Virol. 50:42-49.
7. Belec, L., A. Jean Georges, M. C. Hallouin, A. Si Mohamed, L. Morand-Joubert, and M. C. Georges-Courbot. 1996. Human T-lymphotropic virus type I excretion and specific antibody response in paired saliva and cervico-vaginal secretions. AIDS Res. Hum. Retrovir. 12:157-167.
8. Belza, M. J. 2004. Prevalence of HIV, HTLV-I and HTLV-II among female sex workers in Spain, 2000-2001. Eur. J. Epidemiol. 19:279-282.
9. Chen, B. K., K. Saksela, R. Andino, and D. Baltimore. 1994. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 68:654-660.
10. Chou, T. C. 1976. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 59:253-276.
11. Chou, T. C., and P. Talalay. 1981. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:207-216.
12. Dehee, A., R. Cesaire, N. Desire, A. Lezin, O. Bourdonne, O. Bera, Y. Plumelle, D. Smadja, and J. C. Nicolas. 2002. Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. J. Virol. Methods 102:37-51.
13. de The, G., and M. Kazanji. 1996. An HTLV-I/II vaccine: from animal models to clinical trials? J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13(Suppl. 1):S191-S198.
14. Dezzutti, C. S., V. N. James, A. Ramos, S. T. Sullivan, A. Siddig, T. J. Bush, L. A. Grohskopf, L. Paxton, S. Subbarao, and C. E. Hart. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48:3834-3844.
15. Dokhelar, M. C., H. Pickford, J. Sodroski, and W. A. Haseltine. 1989. HTLV-I p27rex regulates gag and env protein expression. J. Acquir. Immune Defic. Syndr. 2:431-440.
16. Gantlett, K. E., J. N. Weber, and Q. J. Sattentau. 2007. Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antivir. Res. 75:188-197.
17. Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender, and G. de The. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet ii:407-410.
18. Ghez, D., Y. Lepelletier, S. Lambert, J. M. Fourneau, V. Blot, S. Janvier, B. Arnulf, P. M. van Endert, N. Heveker, C. Pique, and O. Hermine. 2006. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J. Virol. 80:6844-6854.
19. Hinuma, Y., K. Nagata, M. Hanaoka, M. Nakai, T. Matsumoto, K. I. Kinoshita, S. Shirakawa, and I. Miyoshi. 1981. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 78:6476-6480.
20. Igakura, T., J. C. Stinchcombe, P. K. Goon, G. P. Taylor, J. N. Weber, G. M. Griffiths, Y. Tanaka, M. Osame, and C. R. Bangham. 2003. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299:1713-1716.
21. Ito, M., M. Baba, A. Sato, R. Pauwels, E. De Clercq, and S. Shigeta. 1987. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antivir. Res. 7:361-367.
22. Jassal, S. R., M. D. Lairmore, A. J. Leigh-Brown, and D. W. Brighty. 2001. Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells. Virus Res. 78:17-34.
23. Jassal, S. R., R. G. Pohler, and D. W. Brighty. 2001. Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin. J. Virol. 75:8317-8328.
24. Javan, C. M., N. J. Gooderham, R. J. Edwards, D. S. Davies, and S. Shaunak. 1997. Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res. Hum. Retrovir. 13:875-880.
25. Kajiyama, W., S. Kashiwagi, H. Ikematsu, J. Hayashi, H. Nomura, and K. Okochi. 1986. Intrafamilial transmission of adult T cell leukemia virus. J. Infect. Dis. 154:851-857.
26. Kwok, S., D. Kellogg, G. Ehrlich, B. Poiesz, S. Bhagavati, and J. J. Sninsky. 1988. Characterization of a sequence of human T cell leukemia virus type I from a patient with chronic progressive myelopathy. J. Infect. Dis. 158:1193-1197.
27. Larsen, O., S. Andersson, Z. da Silva, K. Hedegaard, A. Sandstrom, A. Naucler, F. Dias, M. Melbye, and P. Aaby. 2000. Prevalences of HTLV-1 infection and associated risk determinants in an urban population in Guinea-Bissau, West Africa. J. Acquir. Immune Defic. Syndr. 25:157-163.
28. Laurendeau, I., M. Bahuau, N. Vodovar, C. Larramendy, M. Olivi, I. Bieche, M. Vidaud, and D. Vidaud. 1999. TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency. Clin. Chem. 45:982-986.
29. Lederman, M. M., R. E. Offord, and O. Hartley. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6:371-382.
30. Madan, R. P., M. J. Keller, and B. C. Herold. 2006. Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr. Opin. Infect. Dis. 19:49-54.
31. Manel, N., F. J. Kim, S. Kinet, N. Taylor, M. Sitbon, and J. L. Battini. 2003. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115:449-459.
32. Mayer, K. H., S. A. Karim, C. Kelly, L. Maslankowski, H. Rees, A. T. Profy, J. Day, J. Welch, and Z. Rosenberg. 2003. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17:321-329.
33. Moulard, M., H. Lortat-Jacob, I. Mondor, G. Roca, R. Wyatt, J. Sodroski, L. Zhao, W. Olson, P. D. Kwong, and Q. J. Sattentau. 2000. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:1948-1960.
34. Murphy, E. L., J. P. Figueroa, W. N. Gibbs, A. Brathwaite, M. Holding-Cobham, D. Waters, B. Cranston, B. Hanchard, and W. A. Blattner. 1989. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann. Intern. Med. 111:555-560.
35. Murphy, E. L., R. Wilks, B. Hanchard, B. Cranston, J. P. Figueroa, W. N. Gibbs, J. Murphy, and W. A. Blattner. 1996. A case-control study of risk factors for seropositivity to human T-lymphotropic virus type I (HTLV-I) in Jamaica. Int. J. Epidemiol. 25:1083-1089.
36. Nakashima, K., S. Kashiwagi, W. Kajiyama, M. Hirata, J. Hayashi, A. Noguchi, K. Urabe, K. Minami, and Y. Maeda. 1995. Sexual transmission of human T-lymphotropic virus type I among female prostitutes and among patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan. Am. J. Epidemiol. 141:305-311.
37. Okochi, K., H. Sato, and Y. Hinuma. 1984. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang. 46:245-253.
38. Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, A. Igata, M. Matsumoto, and M. Tara. 1986. HTLV-I associated myelopathy, a new clinical entity. Lancet i:1031-1032.
39. Pinon, J. D., S. M. Kelly, N. C. Price, J. U. Flanagan, and D. W. Brighty. 2003. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein. J. Virol. 77:3281-3290.
40. Pinon, J. D., P. J. Klasse, S. R. Jassal, S. Welson, J. Weber, D. W. Brighty, and Q. J. Sattentau. 2003. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J. Virol. 77:9922-9930.
41. Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77:7415-7419.
42. Proietti, F. A., A. B. Carneiro-Proietti, B. C. Catalan-Soares, and E. L. Murphy. 2005. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24:6058-6068.
43. Rusconi, S., M. Moonis, D. P. Merrill, P. V. Pallai, E. A. Neidhardt, S. K. Singh, K. J. Willis, M. S. Osburne, A. T. Profy, J. C. Jenson, and M. S. Hirsch. 1996. Naphthalene sulfonate polymers with CD4-blocking and antihuman immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40:234-236.
44. Shaunak, S., N. J. Gooderham, R. J. Edwards, N. Payvandi, C. M. Javan, N. Baggett, J. MacDermot, J. N. Weber, and D. S. Davies. 1994. Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br. J. Pharmacol. 113:151-158.
45. Shaunak, S., M. Thornton, S. John, I. Teo, E. Peers, P. Mason, T. Krausz, and D. S. Davies. 1998. Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS. AIDS 12:399-409.
46. Sugiyama, H., H. Doi, K. Yamaguchi, Y. Tsuji, T. Miyamoto, and S. Hino. 1986. Significance of postnatal mother-to-child transmission of human T-lymphotropic virus type-I on the development of adult T-cell leukemia/ lymphoma. J. Med. Virol. 20:253-260.
47. Tajima, K., S. Tominaga, and T. Suchi. 1986. Malignant lymphomas in Japan: epidemiological analysis on adult T-cell leukemia/lymphoma. Hematol. Oncol. 4:31-44.
48. Van Damme, L. 2004. Clinical microbicide research: an overview. Trop. Med. Int. Health 9:1290-1296.
49. Van Damme, L., A. Wright, K. Depraetere, I. Rosenstein, V. Vandersmissen, L. Poulter, M. McKinlay, E. Van Dyck, J. Weber, A. Profy, M. Laga, and V. Kitchen. 2000. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. 76:126-130.
50. Weber, J., K. Desai, and J. Darbyshire. 2005. The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med. 2:e142.
51. Weber, J., A. Nunn, T. O'Connor, D. Jeffries, V. Kitchen, S. McCormack, J. Stott, N. Almond, A. Stone, and J. Darbyshire. 2001. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 15:1563-1568.
52. Yakova, M., A. Lezin, F. Dantin, G. Lagathu, S. Olindo, G. Jean-Baptiste, S. Arfi, and R. Cesaire. 2005. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2:4.
53. Yoshida, M., I. Miyoshi, and Y. Hinuma. 1982. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. USA 79:2031-2035.